ModifiedUnitedHealthcarePolicy CS132.Q

Noncontact Warming Therapy, Ultrasound Therapy, and Fluorescence Imaging for Wounds

Defines UnitedHealthcare's commercial coverage stance for noncontact normothermic wound warming, low-frequency ultrasound therapies (including MIST/NLFU) and real-time fluorescence wound imaging for detection of bacterial presence in wounds; applies to members except in states with state-specific guidance.

Policy Summary

PayerUnitedHealthcare

PolicyNoncontact Warming Therapy, Ultrasound Therapy, and Fluorescence Imaging for Wounds

Policy CodePolicy CS132.Q

Change TypeCoding and template updatesmaterial coding revision

Effective DateFebruary 1, 2026

Next Review DateN/A

Key ActionObtain and verify prior authorization per the member's benefit plan when submitting claims for the listed procedure codes.

SourceLink

POLICY UPDATE CHANGES

Updated list of applicable CPT codes to reflect annual edits; revised description for 0598T and 0599T.

Removed content/language pertaining to the state of Louisiana.

3technologies reviewed

6codes listed

insufficient evidencecoverage rationale

multipleevidence sources

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

92.6%fluorescence peak sensitivity

Coverage Determination and Evidence Summary

Overall coverage determination

Covered when ALL of the following are met:

Policy conclusions: Warming therapy (NNWT) and low-frequency ultrasound therapy are considered unproven and not medically necessary for treating wounds due to insufficient evidence of efficacy; noncontact real-time fluorescence wound imaging for detection of bacterial presence (e.g., MolecuLight i:X) is considered unproven and not medically necessary due to insufficient evidence of safety and/or efficacy.

Direct policy conclusion based on evidence review.

Evidence-based coverage implications

Summary of evidence and implications for coverage decisions:

Low-dose/high-frequency therapeutic ultrasound (weekly): A large multicenter RCT (Watson et al. 2011, n=337) found no difference in time to healing or complete healing and observed significantly more adverse events in the ultrasound group; routine weekly low-dose/high-frequency therapeutic ultrasound is not supported for increasing ulcer healing rates.RCT negative

Watson et al. 2011

Low-frequency noncontact ultrasound (thrice-weekly or pilot regimens): Small randomized pilot data (e.g., limited DFU pilot studies) suggest possible percent area reduction benefits with more frequent NLFU dosing, but these findings are preliminary and require confirmation in larger, well-powered trials before broad coverage is supported.pilot positive but unconfirmed

Pilot evidence only

Noncontact real-time fluorescence imaging (autofluorescence): Observational and diagnostic-accuracy studies report improved sensitivity for detecting moderate-to-heavy bacterial loads compared with clinical assessment alone, and a pilot RCT (Rahma et al., n=56) showed higher 12-week healing proportion when management was informed by autofluorescence imaging; however, ECRI and other assessments conclude evidence is insufficient to demonstrate improved patient-centered outcomes, so routine coverage is not supported without additional confirmatory RCTs.diagnostic accuracy present but outcome benefit unproven

Multiple studies and ECRI assessment

Evidence and guideline-based criteria

Clinical evidence summary and guideline recommendations relevant to coverage:

Fluorescence imaging evidence stance: ECRI's clinical evidence assessment finds the evidence for MolecuLight i:X inconclusive for improving patient outcomes; studies demonstrate higher sensitivity for detecting moderate-to-heavy bacterial loads but lack RCT data showing patient-centered outcome improvements.evidence inconclusive

ECRI 2021 (updated 2024); Le et al. observational data

Role as adjunct to clinical assessment: Multiple studies (Serena et al., Hurley et al., Le et al.) report that fluorescence imaging increases detection sensitivity for bacterial burden and can identify wounds with moderate-to-heavy loads missed by clinical signs alone; recommended use is as an adjunct to clinical signs and symptoms (CSS) assessment, not as a standalone diagnostic.adjunctive use

Serena et al.; Hurley et al.; Le et al.

Guideline recommendations for ultrasound and warming therapies:

This Medical Policy does not apply to states with state-specific policy or guideline versions. Refer to the listed state‑specific policies where indicated for coverage determinations: Idaho, Indiana, Kansas, Kentucky, Nebraska, New Jersey, New Mexico, North Carolina, Ohio, Pennsylvania, and Tennessee.

A clinical evidence assessment by ECRI concluded that the evidence for the MolecuLight i:X Fluorescence Imaging System is inconclusive for improving patient outcomes. Observational studies demonstrate the device may better identify wounds with elevated bacterial loads, but current studies do not provide sufficient evidence that use of the device leads to improved patient‑centered outcomes; additional randomized controlled trials are needed to confirm safety and effectiveness.

Fluorescence imaging may have limitations or be unreliable in certain wound conditions. Reported device incompatibilities include active wound bleeding and the presence of dressings that contain silver, which can interfere with fluorescence signals and sampling accuracy; these factors should be considered when interpreting imaging results or obtaining confirmatory cultures.

Based on the available evidence review, noncontact normothermic wound therapy (NNWT) and low‑frequency ultrasound therapy are considered unproven and not medically necessary for treating wounds. Similarly, real‑time fluorescence wound imaging (including MolecuLight i:X) is considered unproven and not medically necessary due to insufficient evidence of safety and/or efficacy for improving patient‑centered outcomes.

A large multicenter randomized controlled trial (Watson et al., 2011; n=337) evaluating weekly low‑dose, high‑frequency therapeutic ultrasound for up to 12 weeks found no increase in ulcer healing rates, no improvement in health‑related quality of life, and reported a higher rate of adverse events in the ultrasound group compared with standard care, indicating the regimen did not improve clinical outcomes.

Although diagnostic studies show fluorescence imaging can increase detection of moderate‑to‑heavy bacterial loads, the current evidence does not support routine use of the MolecuLight i:X solely to reduce wound closure time or as a replacement for standard diagnostic methods. NICE and ECRI assessments report limited or inconclusive evidence that MolecuLight i:X reduces time to wound closure or improves antibiotic stewardship, and additional RCTs are required to establish clinical benefit.

Applicable Procedure and Supply Codes

Applicable Codes (listed for reference)mixed

0598T	Real-time fluorescence wound imaging with clinical darkness, to identify location of bacterial wound pathogens and measure wound size, per session; first anatomic site (e.g., lower extremity, right leg).
0599T	Real-time fluorescence wound imaging with clinical darkness, to identify location of bacterial wound pathogens and measure wound size, per session; each additional anatomic site (e.g., upper extremity, left leg) (List separately in addition to code for primary procedure).
97610	Low frequency, non-contact, non-thermal ultrasound, including topical application(s), when performed, wound assessment, and instruction(s) for ongoing care, per day.
A6000	Noncontact wound-warming wound cover for use with the noncontact wound- warming device and warming card.
E0231	Noncontact wound-warming device (temperature control unit, AC adapter and power cord) for use with warming card and wound cover.
E0232	Warming card for use with the noncontact wound-warming device and noncontact wound warming- wound cover.

Applicable CPT/HCPCS codes (updated)CPT | HCPCS

0598T	procedure code description revised in policy
0599T	procedure code description revised in policy

Regulatory/Classificationsmixed

FDA 510(k)

Clearance status for MolecuLight i:X and other devices (informational)

Bacterial load thresholds used in studies and device detection references

Device/Study detection thresholdsFluorescence imaging studies and device evaluations reference detection across bacterial loads from 10^4 to 10^9 CFU/g; sensitivity improves at higher loads (e.g., peaks near >10^8 CFU/g).

Microbiology study thresholdsSome clinical microbiology reference methods and study analyses report analytical thresholds or comparisons using 10^5 CFU/g as a study benchmark for bacterial burden.

Clinical diagnostic comparisonsDiagnostic accuracy studies compared fluorescence imaging performance versus SEM/PCR and culture-based methods across thresholds (10^4–10^9 CFU/g) to establish sensitivity and specificity.

Reported performance at graft-prediction cohortOne cohort reported sensitivity 86%, specificity 98%, PPV 72%, NPV 99%, and accuracy 94% for predicting graft loss using fluorescence signals (comparative microbiology swab sensitivity 30%).

Most actionable: practical detection range

Authorization, Documentation, and Billing Guidance

Prior Authorization

Prior Authorization Likely Required

Prior authorization is likely required for novel wound imaging technologies (e.g., noncontact real-time fluorescence imaging such as MolecuLight i:X) and for therapeutic/low-frequency ultrasound wound devices when used outside established, covered indications. Inclusion of procedure codes in this policy (including 0598T, 0599T, and 97610) is for reference only and does not guarantee coverage; verify plan-specific prior authorization requirements before providing services.

Verify prior authorization per member's benefit plan and contractual requirements
Listing of codes does not imply coverage — confirm coverage and PA rules before scheduling

Denial Risk

Denial Risk / Adverse Events Observed

Higher adverse event rates were observed in randomized trials of low-frequency therapeutic ultrasound; exercise operational caution and document any adverse events when using ultrasound devices in wound care.

Clinical Context and Technology Descriptions

Background: Noncontact normothermic wound therapy (NNWT) uses a wound cover and warming unit to apply radiant heat and maintain high humidity with the goal of increasing local temperature, blood flow, and oxygenation. Low‑frequency ultrasound modalities (e.g., MIST/NLFU) deliver ultrasonic energy, often via a saline mist or noncontact handset, intended to cleanse or debride and potentially stimulate healing. Real‑time fluorescence wound imaging (e.g., MolecuLight i:X) uses handheld violet‑light autofluorescence to visualize red or cyan signals that correlate with moderate‑to‑heavy bacterial loads and to guide targeted sampling or debridement. Current evidence reviews conclude that NNWT and low‑frequency ultrasound are unproven and not medically necessary, and fluorescence imaging is unproven for improving patient‑centered outcomes despite demonstrating improved detection sensitivity for bacterial burden; further well‑designed RCTs are needed to determine clinical effectiveness.

Terms and Technology Definitions

Noncontact normothermic wound therapy (NNWT) definition

DefinitionNoncontact normothermic wound therapy (NNWT) uses a noncontact wound cover and a warming unit to apply radiant heat and maintain near-100% relative humidity to raise wound temperature, with the intent of increasing local blood flow and oxygen to the wound.

Delivery methodAn occlusive wound cover paired with a temperature control unit (warming device) provides localized warming without direct contact to the wound bed.

Intended physiologic effectAims to raise wound temperature to increase perfusion and oxygenation as a mechanism to support wound healing (evidence for clinical efficacy is limited).

Low-frequency ultrasound (MIST/NLFU) definition

DefinitionLow-frequency ultrasound (MIST/NLFU) delivers ultrasonic energy at low frequency (approximately 20–40 kHz or ~40 kHz per device specifications) often via a saline mist or noncontact handset to cleanse and debride wounds and potentially stimulate cellular processes that aid healing.

Policy Summary

PayerUnitedHealthcare

PolicyNoncontact Warming Therapy, Ultrasound Therapy, and Fluorescence Imaging for Wounds

Policy CodePolicy CS132.Q

Change TypeCoding and template updatesmaterial coding revision

Effective DateFebruary 1, 2026

Next Review DateN/A

Key ActionObtain and verify prior authorization per the member's benefit plan when submitting claims for the listed procedure codes.

SourceLink

On This Page

Professional guidance (AAWC) and health-technology reviews (NICE) indicate low-frequency ultrasound may have a potential role when combined with appropriate compression and dressings for venous or mixed etiology ulcers, but evidence is limited; warming therapy has insufficient evidence of healing efficacy to support routine use.

AAWC 2015; NICE MIST guidance; NICE Medtech briefing

Fluorescence imaging reliably identifies moderate-to-heavy bacterial loads typically referenced at or above 10^4 CFU/g, with detection performance increasing at higher loads (highlighted for clinical relevance).

Bacterial load indicating concern (> 10^4 CFU/g)

Threshold value>= 10^4 CFU/g is referenced as a bacterial load indicating clinical concern or potential to inhibit healing.

Evidence sourceECRI evidence assessment and Le et al. observational data note CSS missed ~85% of bacterial loads >10^4 CFU/g and fluorescence imaging increased detection sensitivity.

Clinical implicationLoads at or above this threshold are used to define the concept of chronic inhibitory bacterial load (CIBL) and to prompt earlier targeted interventions in studies.

Document adverse events in the medical record and on claims as applicable
Consider risk–benefit given lack of demonstrated clinical benefit for many wound ultrasound applications

Documentation Required

Documentation Required for Fluorescence Imaging Use

When using fluorescence imaging, document digital wound measurements, fluorescence findings, and any resulting targeted interventions (for example, focused debridement). Provide confirmatory clinical microbiology when used to guide therapy per plan requirements.

Record both manual and digital wound area measurements when available
Document fluorescence pattern/grade, location of positive fluorescence, and clinical actions taken (e.g., targeted debridement)
Attach microbiology results when used to justify antimicrobial therapy or changes in management

Note

Fluorescence Imaging Often Used as an Adjunct to Guide Care

Studies often used fluorescence imaging to augment standard wound care and to guide interventions such as targeted debridement; however, evidence is currently inconclusive for improved patient-centered outcomes and additional RCTs are needed. Use of fluorescence imaging should be considered adjunctive to clinical assessment and supported by documentation if submitted for coverage consideration.

Fluorescence imaging was commonly paired with targeted debridement in studies showing improved intermediate outcomes (e.g., wound area reduction)
Clinical utility for improving healing or other patient-centered outcomes has not been established — document rationale when used

Note

Conflicts with Plan or Law

In the event of any conflict between this policy and federal, state, or contractual requirements, the applicable law or contract governs. Before applying this policy, confirm and follow any jurisdictional or plan-specific rules that supersede this guidance.

Follow federal/state/contractual requirements that may differ from this policy
If a plan-specific provision mandates coverage, that provision takes precedence

Billing Rule

Coding and Documentation Note

Coding and documentation notes: inclusion of codes in the Applicable Codes section is reference-only; document clinical rationale, measurement methodology (digital vs manual), fluorescence findings, and any confirmatory microbiology when submitting claims for novel imaging or therapeutic modalities.

0598T and 0599T updated descriptions appear in the Applicable Codes section — inclusion does not guarantee coverage
Document wound measurement technique (digital device name/model if used) and serial area calculations (WAR) when relying on imaging to justify treatment changes

Step Therapy

Step Therapy / Utilization Management

Step therapy and other utilization management tools may apply per plan; this policy does not establish a specific step-therapy protocol. Follow plan-specific utilization management requirements.

Check plan for step therapy, prior authorization, and quantity limits before initiating novel wound imaging or ultrasound therapies

Device example and mechanismThe MIST Therapy System uses a handheld transducer vibrating ~40,000 times per second to generate ultrasound waves carried to the wound via a saline mist; treatment is applied ~1 cm from the wound.

Intended clinical actionsDesigned to remove slough, exudate, fibrin, and bacteria from the wound surface and to promote angiogenesis and growth factor production according to manufacturer descriptions; guideline support is limited and evidence is mixed.

Real-time fluorescence wound imaging definition

DefinitionReal-time fluorescence wound imaging is a handheld violet-light autofluorescence technique (e.g., MolecuLight i:X) that captures and documents fluorescent signals from bacteria in wounds to localize areas of elevated bacterial load at point-of-care.

Functional useProvides immediate visualization of red or cyan fluorescence indicating bacterial presence to guide targeted sampling, debridement, and treatment decisions in conjunction with clinical signs and symptoms (CSS).

Limitations notedImaging has limited excitation depth (~1.5 mm) and cannot detect non-porphyrin–producing bacteria (e.g., some Streptococcus and Enterococcus species); evidence for improved patient-centered outcomes is inconclusive per ECRI.

Chronic inhibitory bacterial load (CIBL) concept

ConceptChronic inhibitory bacterial load (CIBL) refers to bacterial burden levels—commonly referenced at or above 10^4 CFU/g—that may inhibit wound healing and warrant earlier intervention along the bacterial–infection continuum.

Clinical roleCIBL is used in studies to justify targeted interventions (e.g., debridement, sampling, antimicrobial stewardship) guided by fluorescence imaging even when classic infection symptoms are absent.

Detection correlationFluorescence imaging studies report increased detection of wounds with bacterial loads meeting CIBL thresholds compared with clinical assessment alone.

Fluorescence imaging (MolecuLight i:X / MLiX) general description

Device descriptionFluorescence imaging (MolecuLight i:X / MLiX) is a handheld, noncontact autofluorescence imaging device that uses violet light illumination to visualize red or cyan fluorescence from bacteria in wounds, enabling localization of areas with elevated bacterial load and possible biofilm at the point of care.

Intended applicationsUsed to augment clinical assessment, guide targeted wound sampling, and inform debridement or other interventions; studies report improved sensitivity versus CSS alone.

Evidence noteWhile diagnostic accuracy and observational data are promising, conclusive evidence that routine use improves patient-centered outcomes is lacking (ECRI 2021/2024).

Fluorescence imaging (MolecuLight i:X) device-specific note

Device-specific noteThe MolecuLight i:X is a handheld autofluorescence imaging device cleared by FDA under 510(k); it visualizes red or cyan fluorescence to indicate moderate-to-heavy bacterial loads and is intended for real-time point-of-care detection and documentation.

Evidence and limitationsClinical observational studies (e.g., Le et al., Hurley et al.) show higher sensitivity than CSS alone, but ECRI finds evidence inconclusive for improving patient outcomes and further RCTs are needed.

Operational considerationDevice performance can be affected by active bleeding or antimicrobial dressings (e.g., silver), which may limit utility and sampling accuracy in some wounds.

Noncontact low-frequency ultrasound (MIST/UltraMIST) definition

DefinitionNoncontact low-frequency ultrasound (MIST/UltraMIST) refers to low-energy ultrasound delivered via a saline mist or noncontact handset (approximately 20–40 kHz or device-specified ~40 kHz) intended to cleanse and maintain debridement of wounds and promote healing.

Device examples and regulationThe MIST Therapy System and UltraMIST are noncontact low-frequency ultrasound devices regulated as FDA Class II devices and cleared via 510(k) for wound cleansing and maintenance debridement.

Clinical guidanceGuidelines (AAWC) and systematic reviews suggest possible adjunctive benefit for non-healing venous/mixed ulcers when used with compression and moisture-retentive dressings, but overall evidence and application parameters are limited.

Warming therapy (Warm-Up Active Wound Therapy) definition and FDA clearance note

Definition and deviceWarming therapy (Warm-Up Active Wound Therapy) is an occlusive heated dressing system cleared by the FDA (510(k), Warm-Up Active Wound Therapy by Augustine Medical) intended to provide localized wound warming and humidification.

Regulatory noteWarm-Up received 510(k) clearance (March 28, 1997) as a wound and burn occlusive heated dressing (product code MSA); FDA clearance is informational and not a coverage determination.

Evidence summarySystematic reviews and guideline statements report insufficient evidence that warming therapy improves wound healing outcomes; clinical efficacy is limited in the literature.